Akoya Biosciences, which provides spatial biology solutions for discovery and clinical research, announced terms for its IPO on Monday.
The Marlborough, MA-based company plans to raise $125 million by offering 6.6 million shares at a price range of $18 to $20. At the midpoint of the proposed range, Akoya Biosciences would command a fully diluted market value of $753 million.
Akoya delivers spatial biology solutions focused on transforming discovery and clinical research. Through its CODEX and Phenoptics platforms, reagents, software and services, the company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum, from discovery through translational and clinical research.
Akoya Biosciences was founded in 2015 and booked $42 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol AKYA. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity are the joint bookrunners on the deal. It is expected to price during the week of April 12, 2021.
